Literature DB >> 11410685

Molecular screening for fragile X syndrome in mentally handicapped children in Korea.

S H Kwon1, K S Lee, M C Hyun, K E Song, J K Kim.   

Abstract

Fragile X syndrome is one of the most common forms of inherited mental retardation and is caused by the expansion of the CGG trinucleotide repeats in the FMR-1 gene. This study was aimed to facilitate the molecular screening of fragile X syndrome in Korean children with mental retardation of unknown etiology. The subjects were tested by Expand Long Template PCR system in the presence of 7-deaza-dGTP, and then by Southern blot analysis. The PCR method provided rapid and reliable results for the identification of fragile X negative and positive patients. One hundred one mentally retarded children (78 males and 23 females) were screened by PCR amplification, which detected only one abnormal sample. The PCR-positive case was confirmed by the CGG repeat expansion on Southern blot analysis with a positive cytogenetic result. In conclusion, Expand Long Template PCR may be used as the first screening test for detecting the fragile X syndrome.

Entities:  

Mesh:

Year:  2001        PMID: 11410685      PMCID: PMC3054748          DOI: 10.3346/jkms.2001.16.3.271

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  3 in total

1.  Betaine, dimethyl sulfoxide, and 7-deaza-dGTP, a powerful mixture for amplification of GC-rich DNA sequences.

Authors:  Marco Musso; Renata Bocciardi; Sara Parodi; Roberto Ravazzolo; Isabella Ceccherini
Journal:  J Mol Diagn       Date:  2006-11       Impact factor: 5.568

2.  Screening for FMR1 CGG Repeat Expansion in Thai Patients with Autism Spectrum Disorder.

Authors:  Areerat Hnoonual; Charunee Jankittunpaiboon; Pornprot Limprasert
Journal:  Biomed Res Int       Date:  2021-12-08       Impact factor: 3.411

Review 3.  Fragile X syndrome in Korea: a case series and a review of the literature.

Authors:  Shin-Young Yim; Bo Hyun Jeon; Jung A Yang; Hyon J Kim
Journal:  J Korean Med Sci       Date:  2008-06       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.